Select publications

Borner MM et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002;20(7):1759-66. Abstract

Cassidy J et al. XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22(11):2084-91. Abstract

De Gramont A et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: Results of the international randomized MOSAIC trial. Proc ASCO 2003;Abstract 1015.

De Gramont A et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: Safety results of the international randomized AI trial. Proc ASCO 2002;Abstract 525.

Fyfe GA et al. Bevacizumab plus irinotecan/5-FU/leocovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups. J Clin Oncol 2004;22(14 Suppl):9-13;Abstract 3617.

Giantonio B et al. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc ASCO GI Cancer Symposium 2005;Abstract 169a.

Goldberg RM et al. N9741: FOLFOX (oxaliplatin(Oxal)/5-fluorouracil(5-FU)/leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU/LV) in advanced colorectal cancer (CRC): Final efficacy data from an Intergroup study. J Clin Oncol 2004;22(14 Suppl);Abstract 3621.

Hochster HS et al. Bevacizumab (B) with oxaliplatin (O)-based chemotherapy in the firstline therapy of metastatic colorectal cancer (mCRC): Preliminary results of the randomized “TREE-2” trial. Proc ASCO GI Cancer Symposium 2005;Abstract 241.

Hurwitz H. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 2004;4(Suppl 2):62-8. Abstract

Hurwitz H et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc ASCO 2003;Abstract 3646.

Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42. Abstract

Kabbinavar F et al. Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/ leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21(1):60-5. Abstract

Saltz LB et al. Interim report of randomized phase II trial of cetuximab/bevacizumab/ irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc ASCO GI Cancer Symposium 2005;Abstract 169b.

Saltz LB et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin (FL) alone in stage III colon cancer (Intergroup trial CALGB C89803). J Clin Oncol 2004;22(14 Suppl);Abstract 3500.

Scheithauer W et al. Randomized multicenter Phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003;21(7):1307-12. Abstract

Willett CG et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10(2):145-7.Abstract

Wolmark N et al. A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: Results of NSABP Protocol C-06. J Clin Oncol 2004;22(14 Suppl);Abstract 3508.

Zeuli M et al. Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol 2003;14(9):1378-82. Abstract